Study of Selumetinib (AZD6244)(ARRY-142886) in Combination with Irinotecan in Previously Treated Patients with Colorec
Study identifier:D9010C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination with Irinotecan, in 2nd Line Patients with K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer
Medical condition
Colorectal Cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD6244, Irinotecan
Sex
All
Actual Enrollment
32
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Apr 2010
Primary Completion Date: 01 Jul 2012
Study Completion Date: 01 Jul 2012
Study design
Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Selumetinib (AZD6244) in combination with irinotecan | Drug: AZD6244 50 or 75mg, capsules, PO, BID, 28 days Other Name: Selumetinib Drug: Irinotecan 180mg/m2, IV, Day 1& 15 of each cycle Other Name: Camptosar; Campto |
Contacts
Investigators
Principal Investigator
Howard Hochster
Yale Comprehensive Cancer Center
